{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T03:36:15Z","timestamp":1789011375297,"version":"build-2803163510"},"reference-count":46,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,2,12]],"date-time":"2016-02-12T00:00:00Z","timestamp":1455235200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["bbmt.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biology of Blood and Marrow Transplantation"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1016\/j.bbmt.2016.02.004","type":"journal-article","created":{"date-parts":[[2016,2,16]],"date-time":"2016-02-16T16:00:24Z","timestamp":1455638424000},"page":"1030-1036","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Quantification of Acute Lymphoblastic Leukemia Clonotypes in Leukapheresed Peripheral Blood Progenitor Cells Predicts Relapse Risk after Autologous Hematopoietic Stem Cell Transplantation"],"prefix":"10.1016","volume":"22","author":[{"given":"Gabriel N.","family":"Mannis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"III","given":"Thomas G.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lloyd E.","family":"Damon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4681-6227","authenticated-orcid":false,"given":"Charalambos","family":"Andreadis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca L.","family":"Olin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine A.","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malek","family":"Faham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jimmy","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiyun Z.","family":"Ai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin M.L.","family":"Gaensler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter H.","family":"Sayre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey L.","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron C.","family":"Logan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bbmt.2016.02.004_bib1","first-page":"5","article-title":"Cancer Statistics, 2015","volume":"65","author":"Siegel","year":"2015","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.bbmt.2016.02.004_bib2","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.1182\/blood.V97.5.1211","article-title":"Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01","volume":"97","author":"Silverman","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.02.004_bib3","doi-asserted-by":"crossref","first-page":"3760","DOI":"10.1182\/blood-2005-04-1623","article-title":"Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII\/ECOG E2993","volume":"106","author":"Rowe","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.02.004_bib4","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1038\/bmt.2014.312","article-title":"Hematopoietic SCT in Europe 2013: recent trends in the use of alternative donors showing more haploidentical donors but fewer cord blood transplants","volume":"50","author":"Passweg","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.02.004_bib5","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1038\/sj.leu.2400959","article-title":"The impact of age on outcome in lymphoblastic leukaemia; MRC UKALL X and XA compared: a report from the MRC Paediatric and Adult Working Parties","volume":"12","author":"Chessells","year":"1998","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2016.02.004_bib6","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1182\/blood.V71.1.123.123","article-title":"Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults","volume":"71","author":"Hoelzer","year":"1988","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.02.004_bib7","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1182\/blood-2006-10-051912","article-title":"Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII\/Eastern Cooperative Oncology Group (ECOG) 2993 trial","volume":"109","author":"Moorman","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.02.004_bib8","doi-asserted-by":"crossref","first-page":"3434","DOI":"10.1182\/blood-2004-07-2922","article-title":"A\u00a0comprehensive genetic classification of adult acute lymphoblastic leukemia (ALL): analysis of the GIMEMA 0496 protocol","volume":"105","author":"Mancini","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.02.004_bib9","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1182\/blood-2005-07-2708","article-title":"Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia","volume":"107","author":"Br\u00fcggemann","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.02.004_bib10","unstructured":"National Comprehensive Cancer Network Guidelines: Acute Lymphoblastic Leukemia. Version 2.2014. Available at: http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/all.pdf. Accessed June 2,\u00a02015."},{"key":"10.1016\/j.bbmt.2016.02.004_bib11","doi-asserted-by":"crossref","first-page":"1990","DOI":"10.1200\/JCO.1993.11.10.1990","article-title":"Adult acute lymphoblastic leukemia: a multicentric randomized trial testing bone marrow transplantation as postremission therapy. The French Group on Therapy for Adult Acute Lymphoblastic Leukemia","volume":"11","author":"Fi\u00e8re","year":"1993","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2016.02.004_bib12","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1182\/blood-2007-10-116582","volume":"111","author":"Goldstone","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.02.004_bib13","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1038\/sj.leu.2404065","article-title":"Autologous stem cell transplantation in adults with acute lymphoblastic leukemia in first complete remission: analysis of the LALA-85, -87 and -94 trials","volume":"20","author":"Dh\u00e9din","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2016.02.004_bib14","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/sj.bmt.1705144","article-title":"Imatinib interim therapy between chemotherapeutic cycles and in\u00a0vivo purging before autologous stem cell transplantation, followed by maintenance therapy is a feasible treatment strategy in Philadelphia chromosome-positive acute lymphoblastic leukemia","volume":"36","author":"Shin","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.02.004_bib15","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/sj.bmt.1705952","article-title":"Long-term outcomes of adults with acute lymphoblastic leukemia after autologous or unrelated donor bone marrow transplantation: a comparative analysis by the National Marrow Donor Program and Center for International Blood and Marrow Transplant Research","volume":"41","author":"Bishop","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.02.004_bib16","doi-asserted-by":"crossref","first-page":"111","DOI":"10.3324\/haematol.2013.085811","article-title":"Autologous transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia achieves outcomes similar to allogeneic transplantation: results of CALGB Study 10001 (Alliance)","volume":"99","author":"Wetzler","year":"2014","journal-title":"Haematologica"},{"key":"10.1016\/j.bbmt.2016.02.004_bib17","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/bmt.2010.125","article-title":"Autologous hematopoietic cell transplantation for high-risk ALL","volume":"46","author":"Linker","year":"2011","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.02.004_bib18","doi-asserted-by":"crossref","first-page":"4153","DOI":"10.1182\/blood-2008-11-185132","article-title":"Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL)","volume":"113","author":"Bassan","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.02.004_bib19","doi-asserted-by":"crossref","first-page":"4470","DOI":"10.1182\/blood-2012-06-379040","article-title":"Has MRD monitoring superseded other prognostic factors in adult ALL?","volume":"120","author":"Br\u00fcggemann","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.02.004_bib20","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1182\/blood-2011-09-377713","article-title":"Adult patients with acute lymphoblastic leukemia and molecular failure display a poor prognosis and are candidates for stem cell transplantation and targeted therapies","volume":"120","author":"G\u00f6kbuget","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.02.004_bib21","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1007\/s11899-015-0252-7","article-title":"Minimal residual disease monitoring in adult ALL to determine therapy","volume":"10","author":"Bassan","year":"2015","journal-title":"Curr Hematol Malig Rep"},{"key":"10.1016\/j.bbmt.2016.02.004_bib22","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1016\/j.bbmt.2014.04.018","article-title":"Immunoglobulin and T cell receptor gene high-throughput sequencing quantifies minimal residual disease in acute lymphoblastic leukemia and predicts post-transplantation relapse and survival","volume":"20","author":"Logan","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.bbmt.2016.02.004_bib23","doi-asserted-by":"crossref","first-page":"5173","DOI":"10.1182\/blood-2012-07-444042","article-title":"Deep-sequencing approach for minimal residual disease detection in acute lymphoblastic leukemia","volume":"120","author":"Faham","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.02.004_bib24","doi-asserted-by":"crossref","first-page":"3206","DOI":"10.1182\/blood-2009-10-248146","article-title":"Molecular response to treatment redefines all prognostic factors in children and adolescents with B-cell precursor acute lymphoblastic leukemia: results in 3184 patients of the AIEOP-BFM ALL 2000 study","volume":"115","author":"Conter","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.02.004_bib25","doi-asserted-by":"crossref","first-page":"2691","DOI":"10.1182\/blood.V96.8.2691","article-title":"Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia","volume":"96","author":"Coustan-Smith","year":"2000","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.02.004_bib26","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1016\/S0140-6736(98)04058-6","article-title":"Prognostic value of minimal residual disease in acute lymphoblastic leukaemia in childhood","volume":"352","author":"van Dongen","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.bbmt.2016.02.004_bib27","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1200\/JCO.2002.20.4.1094","article-title":"Minimal residual disease tests provide an independent predictor of clinical outcome in adult acute lymphoblastic leukemia","volume":"20","author":"Mortuza","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2016.02.004_bib28","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/leu.2014.30","article-title":"Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's Oncology Group study AALL0031","volume":"28","author":"Schultz","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2016.02.004_bib29","doi-asserted-by":"crossref","first-page":"134ra63","DOI":"10.1126\/scitranslmed.3003656","article-title":"High-throughput sequencing detects minimal residual disease in acute T lymphoblastic leukemia","volume":"4","author":"Wu","year":"2012","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.bbmt.2016.02.004_bib30","doi-asserted-by":"crossref","first-page":"4540","DOI":"10.1158\/1078-0432.CCR-13-3231","article-title":"Detection of minimal residual disease in B lymphoblastic leukemia by high-throughput sequencing of IGH","volume":"20","author":"Wu","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.bbmt.2016.02.004_bib31","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1182\/blood-2014-12-615757","article-title":"IgH-V(D)J NGS-MRD measurement pre- and early post-allotransplant defines very low- and very high-risk ALL patients","volume":"125","author":"Pulsipher","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.02.004_bib32","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S1470-2045(15)70106-3","article-title":"Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study","volume":"16","author":"Roschewski","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bbmt.2016.02.004_bib33","doi-asserted-by":"crossref","first-page":"3679","DOI":"10.1182\/blood-2015-03-635169","article-title":"Non-invasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing","volume":"125","author":"Kurtz","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.02.004_bib34","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/bjh.13349","article-title":"Detection of classical Hodgkin lymphoma specific sequence in peripheral blood using a next-generation sequencing approach","volume":"169","author":"Oki","year":"2015","journal-title":"Br J Haematol"},{"key":"10.1016\/j.bbmt.2016.02.004_bib35","doi-asserted-by":"crossref","first-page":"3073","DOI":"10.1182\/blood-2014-01-550020","article-title":"Prognostic value of deep sequencing method for minimal residual disease detection in multiple myeloma","volume":"123","author":"Martinez-Lopez","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.bbmt.2016.02.004_bib36","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1038\/leu.2013.52","article-title":"Minimal residual disease quantification using consensus primers and high-throughput IGH sequencing predicts post-transplant relapse in chronic lymphocytic leukemia","volume":"27","author":"Logan","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2016.02.004_bib37","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.clml.2013.09.013","article-title":"Deep sequencing reveals myeloma cells in peripheral blood in majority of multiple myeloma patients","volume":"14","author":"Vij","year":"2014","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.bbmt.2016.02.004_bib38","doi-asserted-by":"crossref","first-page":"21194","DOI":"10.1073\/pnas.1118357109","article-title":"High-throughput VDJ sequencing for quantification of minimal residual disease in chronic lymphocytic leukemia and immune reconstitution assessment","volume":"108","author":"Logan","year":"2011","journal-title":"Proc Natl Acad Sci U\u00a0S\u00a0A"},{"key":"10.1016\/j.bbmt.2016.02.004_bib39","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1038\/leu.2013.375","article-title":"Next-generation sequencing and real-time quantitative PCR for minimal residual disease detection in B-cell disorders","volume":"28","author":"Ladetto","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.bbmt.2016.02.004_bib40","doi-asserted-by":"crossref","first-page":"4134","DOI":"10.1200\/JCO.2014.56.3247","article-title":"Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia","volume":"32","author":"Topp","year":"2014","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.bbmt.2016.02.004_bib41","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1470-2045(14)71170-2","article-title":"Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study","volume":"16","author":"Topp","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bbmt.2016.02.004_bib42","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for\u00a0sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bbmt.2016.02.004_bib43","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T\u00a0cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.bbmt.2016.02.004_bib44","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1056\/NEJMoa1215134","article-title":"Chimeric antigen receptor-modified T cells for acute lymphoid leukemia","volume":"368","author":"Grupp","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bbmt.2016.02.004_bib45","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/S1470-2045(10)70233-3","article-title":"Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial","volume":"11","author":"Mahon","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.bbmt.2016.02.004_bib46","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1038\/leu.2010.185","article-title":"Patients with chronic myeloid leukemia who maintain a complete molecular response after stopping imatinib treatment have evidence of persistent leukemia by DNA PCR","volume":"24","author":"Ross","year":"2010","journal-title":"Leukemia"}],"container-title":["Biology of Blood and Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879116001099?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1083879116001099?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T14:55:17Z","timestamp":1761058517000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1083879116001099"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":46,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["S1083879116001099"],"URL":"https:\/\/doi.org\/10.1016\/j.bbmt.2016.02.004","relation":{},"ISSN":["1083-8791"],"issn-type":[{"value":"1083-8791","type":"print"}],"subject":[],"published":{"date-parts":[[2016,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Quantification of Acute Lymphoblastic Leukemia Clonotypes in Leukapheresed Peripheral Blood Progenitor Cells Predicts Relapse Risk after Autologous Hematopoietic Stem Cell Transplantation","name":"articletitle","label":"Article Title"},{"value":"Biology of Blood and Marrow Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bbmt.2016.02.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}